Citations

Clear

89 citation(s) found for "Beckmann, MW".

p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study
Köbel, Martin , Kang, Eunyoung , Weir, Ashley , Rambau, Peter , Nelson, Gregg , Meagher, Nicola S. , Riggan, Marjorie J. , Alsop, Jennifer , Anglesio, Michael S. , Beckmann, Matthias W. , Bisinotto, Christiani, Boisen, M.M. , Boros, Jessica , Brand, Alison H. , Carney, Michael E. , Coulson, Penny , Courtney‐Brooks, Madeleine , Cushing‐Haugen, Kara L. , Deen, Suha , El‐Bahrawy, Mona , Group, AOCS, Fischer, Anna , Gayther, Simon A. , Hartmann, Arndt, Hendley, Joy , Huang, Yajue, Jimenez‐Liñan, Mercedes , Jones, Michael E. , Kennedy, Catherine J. , Kluz, Tomasz , Koziak, Jennifer M. , Lesnock, Jaime, Lester, Jenny , Longacre, Teri A. , Lycke, Maria , Mateoiu, Constantina , McCauley, Bryan M. , McGuire, Valerie , Ney, Britta, Olawaiye, Alexander , Oršulić, Sandra , Osório, Ana , Paz‐Ares, Luis , Rothstein, Joseph H. , Ruebner, Matthias , Shah, Mitul , Sharma, Raghwa , Shvetsov, Yurii B. , Singh, Naveena , Talhouk, Aline , Whittemore, Alice S. , Widschwendter, Martin , Bowtell, David D.L. , Reis, Francisco José Cândido dos , Fasching, Peter A. , García, María J. , Goodman, Marc T. , Goode, Ellen L. , Huntsman, David G. , Kelemen, Linda E. , Kommoss, Stefan , Le, Nhu D. , Menon, Usha , Schildkraut, Joellen M. , Sieh, Weiva , Staebler, Annette , Ramus, Susan J. , Anglesio, Michael S , Erber, Ramona , Gilks, C. Blake , Shvetsov, Yurii B , Campbell, Ian G , Huntsman, David G , Ramus, Susan J , Köbel, Martin , Menon, Usha , Kennedy, Catherine J , Widschwendter, Martin , Jones, Michael E , Sieh, Weiva , Brand, Alison H , Bowtell, David D , Nelson, Gregg S , El-Bahrawy, Mona A , Kluz, Tomasz , Goodman, Marc T , Kang, Eun‐Young, Lee, Cheng‐Han , Ghatage, Prafull , Brooks‐Wilson, Angela , Cybulski, Cezary , Elishaev, Esther , Fereday, Sián , Group, AOCS, Barquín, Arántzazu , Gentry‐Maharaj, Aleksandra , Gronwald, Helena , Grube, Marcel , Harnett, Paul R. , Harris, Holly R. , Hartkopf, Andreas D , Hein, Alexander , Hernandez, Brenda Y. , Jakubowska, Anna , Lubiński, Jan , Cajal, Teresa Ramón y , Schoemaker, Minouk J. , Sherman, Mark E. , Steed, Helen , Storr, Sarah J. , Traficante, Nadia , Wang, Chen , Wilkens, Lynne R. , Winham, Stacey J. , Benı́tez, Javier , Berchuck, Andrew , Campbell, Ian , Cook, Linda S. , DeFazio, Anna , Doherty, Jennifer A. , Fortner, Renée T. , Gronwald, Jacek , Karlan, Beth Y. , Martin, Stewart G. , Modugno, Francesmary , Pharoah, Paul D.P. , Sundfeldt, Karin , Swerdlow, Anthony J. , Brenton, James D.

Mayo Clinic

The Journal of Pathology: Clinical Research | March 22, 2023 | Volume: 9 | Issue: 3 | Pages: 208-222

10.1002/cjp2.311 | PMID 36948887 Get It

AbstractOur objective was to test whether p53 expression status is associated with survival for women diagnosed with the most common ovarian carcinoma histotypes (high‐grade serous carcinoma [HGSC], endometrioid carcinoma [EC], and clear cell carcinoma [CCC]) using a large multi‐institutional cohort from the Ovarian Tumor Tissue Analysis (OTTA) consortium. p53 expression was assessed on 6,678 cases represented on tissue microarrays from 25 participating OTTA study sites using a previously validated immunohistochemical (IHC) assay as a surrogate for the presence and functional effect of TP53 mutations. Three abnormal expression patterns (overexpression, complete absence, and cytoplasmic) and the normal (wild type) pattern were recorded. Survival analyses were performed by histotype. The frequency of abnormal p53 expression was 93.4% (4,630/4,957) in HGSC compared to 11.9% (116/973) in EC and 11.5% (86/748) in CCC. In HGSC, there were no differences in overall survival across the abnormal p53 expression patterns. However, in EC and CCC, abnormal p53 expression was associated with an increased risk of death for women diagnosed with EC in multivariate analysis compared to normal p53 as the reference (hazard ratio [HR] = 2.18, 95% confidence interval [CI] 1.36–3.47, p = 0.0011) and with CCC (HR = 1.57, 95% CI 1.11–2.22, p = 0.012). Abnormal p53 was also associated with shorter overall survival in The International Federation of Gynecology and Obstetrics stage I/II EC and CCC. Our study provides further evidence that functional groups of TP53 mutations assessed by abnormal surrogate p53 IHC patterns are not associated with survival in HGSC. In contrast, we validate that abnormal p53 IHC is a strong independent prognostic marker for EC and demonstrate for the first time an independent prognostic association of abnormal p53 IHC with overall survival in patients with CCC.
Impact of preoperative malperfusion on postoperative outcomes in type A aortic dissection - importance of serum lactate estimation in ongoing malperfusion
Kaufeld, Tim , Beckmann, Erik , Rudolph, Linda, Krüger, Heike, Natanov, Ruslan , Arar, Morsi , Korte, Wilhelm, Kaufeld, Jessica , Schilling, Tobias , Haverich, Axel , Shrestha, Malakh , Martens, Andreas , Rudolph, Linda

Mayo Clinic

Perfusion | February 16, 2023 | Volume: 39 | Issue: 4 | Pages: 733-742

10.1177/02676591231157545 | PMID 36794541 Get It

Introduction Acute type A aortic dissection (ATAAD) is one of the most critical emergencies in cardiovascular surgery. Additional complications such as organ malperfusion can significantly decrease the chances of survival. Despite promptly performed surgical treatment, impaired organ perfusion may persist, thus close postoperative monitoring is recommended. But, is there a surgical consequence due to the existence of a preoperatively known malperfusion and is there a correlation between pre-, peri- and postoperative levels of serum lactate and proven malperfusion? Methods Between 2011 and 2018, 200 patients (66% male; median age: 62.5 years; interquartile range: +/−12.4 years) that received surgical treatment at our institution for an acute dissection DeBakey type I were enrolled in this study. The cohort was divided into two groups according to the preoperative existence of malperfusion and non-malperfusion. At least one kind of malperfusion occurred in 74 patients (Group A: 37%), while 126 patients (Group B: 63%) showed no evidence of malperfusion. Furthermore, lactate levels of both cohorts were differentiated into four periods: preoperative, intraoperative, 24 hours after surgery, and 2–4 days after surgery. Results The patients’ status differed significantly prior to surgery. Group A (malperfusion) showed an elevated requirement for mechanical resuscitation (A: 10.8%; B: 5.6%; p: 0.173), were significantly more often admitted in an intubated state (A: 14.9%; B: 2.4%; p: 0.001) and showed higher incidences of stroke (A: 18.9% ( n = 149); B: 3.2% ( n = 4); p: 0.001). Levels of serum lactate from the preoperative period until days 2–4 were significantly increased in the malperfusion cohort at all times. Conclusions Preexisting malperfusion due to ATAAD may significantly increase the chance of early mortality in patients with ATAAD. Serum lactate levels were a reliable marker for inadequate perfusion from admission until day 4 after surgery. Despite this, early intervention survival in this cohort remains limited.
Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival
Morra, Anna , Andrulis, Irene L. , Beckmann, Matthias W. , Bolla, Manjeet K. , Camp, Nicola J. , Cessna, Melissa H., Chang‐Claude, Jenny , Collaborators, NBCS, Daly, Mary B., Easton, Douglas F. , Eccles, Diana M., Evans, D. Gareth , Fasching, Peter A. , Flyger, Henrik, García‐Closas, Montserrat , Gündert, Melanie , Hahnen, Eric , Haiman, Christopher A. , Hamann, Ute, Harrington, Patricia, Hoppe, Reiner , Howell, Anthony , Investigators, ABCTB, Investigators, kConFab, Janni, Wolfgang, Johnson, Nichola , Kristensen, Vessela N. , Lindblom, Annika , Mannermaa, Arto , Mavroudis, Dimitrios, Nevelsteen, Ines, Neven, Patrick , Obi, Nadia , Offit, Kenneth , Park‐Simon, Tjoung‐Won , Patel, Alpa V. , Phillips, Kelly‐Anne , Plaseska-Karanfilska, Dijana, Rack, Brigitte , Rhenius, Valerie , Sawyer, Elinor J. , Schmutzler, Rita K. , Schuetze, Sabine, Shah, Mitul , Smichkoska, Snezhana , Tollenaar, Rob A.�E.�M. , Tomlinson, Ian , Vachon, Celine M. , Veen, Elke M. van , Wang, Qin , Wendt, Camilla, Wildiers, Hans , Adank, Muriel A. , Hooning, Maartje J. , Eccles, Diana , Plaseska‐Karanfilska, Dijana , Eccles, Diana , Evans, D Gareth , García-Closas, Montserrat , Phillips, Kelly-Anne , Wildiers, Hans , Lindblom, Annika , Plaseska-Karanfilska, Dijana , Sawyer, Elinor J , Schreurs, Maartje A. C. , Anton‐Culver, Hoda , Augustinsson, Annelie , Behrens, Sabine , Bojesen, Stig E. , Brauch, Hiltrud , Broeks, Annegien , Buys, Saundra S. , Castelao, Jose E. , Chung, Wendy K. , Colonna, Sarah V. , Couch, Fergus J. , Cox, Angela , Cross, Simon S. , Czene, Kamila , Dennis, Joe , Devilee, Peter , Dörk, Thilo , Dunning, Alison M. , Dwek, Miriam , Eriksson, Mikael , Fehm, Tanja , Figueroa, Jonine D. , Gabrielson, Marike , Gago-Domínguez, Manuela , García-Sáenz, José Á. , Genkinger, Jeanine M. , Graßmann, Felix , Hartikainen, Jaana M. , Hopper, John L. , Houlston, Richard S. , Jakubowska, Anna , Jernström, Helena , John, Esther M. , Jones, Michael E. , Kurian, Allison W. , Lambrechts, Diether , Marchand, Loı̈c Le , Lubiński, Jan , Lux, Michael P. , Mulligan, Anna Marie , Muranen, Taru , Nevanlinna, Heli , Newman, William G. , Olshan, Andrew F. , Peterlongo, Paolo , Polley, Eric C. , Presneau, Nadège , Pylkäs, Katri , Radice, Paolo , Rashid, Muhammad Usman , Robson, Mark E. , Romero, Atocha , Saloustros, Emmanouil , Scott, Christopher, Southey, Melissa C. , Tapper, William , Teras, Lauren R. , Tomczyk, Katarzyna , Troester, Melissa A. , Vachon, Celine M. , Winqvist, Robert , Ziogas, Argyrios , Hall, Per N , Pharoah, Paul D.P. , Hollestelle, Antoinette , Schmidt, Marjanka K.

Mayo Clinic

No container title available | February 13, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2569372/v1 | PMID 36824750 Get It

Abstract Breast cancer (BC) patients with a germline CHEK2 c.1100delC variant have an increased risk of contralateral BC (CBC) and worse BC-specific survival (BCSS) compared to non-carriers. We aimed to assess the associations of CHEK2 c.1100delC, radiotherapy, and systemic treatment with CBC risk and BCSS. Analyses were based on 82,701 women diagnosed with invasive BC including 963 CHEK2 c.1100delC carriers; median follow-up was 9.1 years. Differential associations of treatment by CHEK2 c.1100delC status were tested by including interaction terms in a multivariable Cox regression model. A multi-state model was used for further insight into the relation between CHEK2 c.1100delC status, treatment, CBC risk and death. There was no evidence for differential associations of therapy with CBC risk by CHEK2 c.1100delC status The strongest association with reduced CBC risk was observed for the combination of chemotherapy and endocrine therapy [HR(95%CI): 0.66 (0.55–0.78)]. No association was observed with radiotherapy. Results from the multi-state model showed shorter BCSS for CHEK2 c.1100delC carriers versus non-carriers also after accounting for CBC occurrence [HR(95%CI) :1.30 (1.09–1.56)]. In conclusion, systemic therapy was associated with reduced CBC risk irrespective of CHEK2 c.1100delC status. Moreover, CHEK2 c.1100delC carriers had shorter BCSS, which appears not to be fully explained by their CBC risk. (Main MS: 3201 words)
Lifetime ovulatory years and risk of epithelial ovarian cancer: a multinational pooled analysis
Fu, Zhuxuan , Irvin, Sarah , Anton‐Culver, Hoda , Beckmann, Matthias W. , Chang‐Claude, Jenny, Cook, Linda , Cushing‐Haugen, Kara L. , Fasching, Peter A. , Gayther, Simon A. , Giles, Graham G. , Goode, Ellen L. , Kaaks, Rudolf , Kotsopoulos, Joanne , Le, Nhu D. , Matsuo, Keitaro , McGuire, Valerie, McLaughlin, John R, Menon, Usha , Moysich, Kirsten B. , Pearce, Celeste Leigh , Pike, Malcolm C. , Ramus, Susan J. , Riggan, Marjorie J. , Rothstein, Joseph H. , Schildkraut, Joellen M. , Sieh, Weiva , Sutphen, Rebecca , Terry, Kathryn L. , Thompson, Pamela J., Titus, Linda , Altena, Anne M. van , White, Emily, Whittemore, Alice S. , Wu, Anna H. , Wentzensen, Nicolas , Group, AOCS, Risch, Harvey A. , Modugno, Francesmary , Zheng, Wei , Anton-Culver, Hoda , Giles, Graham G , Kaaks, Rudolf , Kotsopoulos, Joanne , Matsuo, Keitaro , Menon, Usha , Ramus, Susan J , Sieh, Weiva , van Altena, Anne M , Ziogas, Argyrios , Wentzensen, Nicolas , Risch, Harvey A , Modugno, Francesmary , Moysich, Kirsten , Zheng, Wei , Fu, Zhuxuan , Goodman, Marc T , Brooks, Maria M. , Jordan, Susan J. , Aben, Katja K.H. , Bandera, Elisa V. , Berchuck, Andrew , Brooks‐Wilson, Angela , Cook, Linda S, Cramer, Daniel W. , Doherty, Jennifer A. , Ekici, Arif B. , Fortner, Renée T. , Gentry‐Maharaj, Aleksandra , Goodman, Marc T. , Harris, Holly R. , Hein, Alexander , Kiemeney, Lambertus A. , Köbel, Martin , Lee, Alice W. , McLaughlin, John R, Milne, Roger L. , Qin, Bo , Zheng, Wei , Ziogas, Argyrios , Taylor, Sarah E , Tang, Lu , Songer, Thomas J. , Webb, Penelope M. , Group, AOCS

Mayo Clinic

JNCI: Journal of the National Cancer Institute | January 23, 2023 | Volume: 115 | Issue: 5 | Pages: 539-551

10.1093/jnci/djad011 | PMID 36688720 Get It

Abstract Background The role of ovulation in epithelial ovarian cancer (EOC) is supported by the consistent protective effects of parity and oral contraceptive use. Whether these factors protect through anovulation alone remains unclear. We explored the association between lifetime ovulatory years (LOY) and EOC. Methods LOY was calculated using 12 algorithms. Odds ratios (ORs) and 95% confidence intervals (CIs) estimated the association between LOY or LOY components and EOC among 26 204 control participants and 21 267 case patients from 25 studies. To assess whether LOY components act through ovulation suppression alone, we compared beta coefficients obtained from regression models with expected estimates assuming 1 year of ovulation suppression has the same effect regardless of source. Results LOY was associated with increased EOC risk (OR per year increase = 1.014, 95% CI = 1.009 to 1.020 to OR per year increase = 1.044, 95% CI = 1.041 to 1.048). Individual LOY components, except age at menarche, also associated with EOC. The estimated model coefficient for oral contraceptive use and pregnancies were 4.45 times and 12- to 15-fold greater than expected, respectively. LOY was associated with high-grade serous, low-grade serous, endometrioid, and clear cell histotypes (ORs per year increase = 1.054, 1.040, 1.065, and 1.098, respectively) but not mucinous tumors. Estimated coefficients of LOY components were close to expected estimates for high-grade serous but larger than expected for low-grade serous, endometrioid, and clear cell histotypes. Conclusions LOY is positively associated with nonmucinous EOC. Differences between estimated and expected model coefficients for LOY components suggest factors beyond ovulation underlie the associations between LOY components and EOC in general and for non-HGSOC.
CCNE1 and survival of patients with tubo‐ovarian high‐grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study
Kang, Eunyoung , Weir, Ashley , Meagher, Nicola S. , Farrington, Kyo , Nelson, Gregg , Lee, Cheng‐Han , Riggan, Marjorie J. , Popović, Gordana , Leung, Betty, Tang, Katrina , Lambie, Neil, Millstein, Joshua , Alsop, Jennifer , Anglesio, Michael S. , Barlow, Ellen , Beckmann, Matthias W. , Berger, Jessica, Bisinotto, Christiani, Bösmüller, Hans , Boros, Jessica , Brand, Alison H. , Carney, Michael E. , Casablanca, Yovanni , Cohen, Paul A. , Coulson, Penny , Courtney‐Brooks, Madeleine , Cunningham, Julie M. , Darcy, Kathleen M. , El‐Bahrawy, Mona A., Farrell, Rhonda , Fischer, Anna , García, María J. , Gayther, Simon A. , Group, AOCS, Harnett, Paul R. , Harrington, Shariska P. , Harter, Philipp , Hartmann, Arndt , Hecht, Jonathan L. , Heikaus, Sebastian, Hendley, Joy , Polo, Susanna Hernando, Heublein, Sabine , Hirasawa, Akira , Huntsman, David G. , Jimenez‐Liñan, Mercedes , Jones, Michael E. , Kennedy, Catherine J. , Khabele, Dineo , Lambrechts, Diether , Le, Nhu D. , Lener, Marcin , Lester, Jenny , Leung, Yee , Linder, Anna , Loverix, Liselore , Madan, Rashna , Maxwell, G. Larry , Olawaiye, Alexander , Oršulić, Sandra , Palacios, José , Pearce, Celeste Leigh , Pike, Malcolm C. , Quinn, Carmel M. , Mohan, Ganendra Raj , Rodríguez‐Antona, Cristina , Ruebner, Matthias , Ryan, Andy , Salfinger, Stuart , Sasamoto, Naoko , Schildkraut, Joellen M. , Schoemaker, Minouk J. , Shah, Mitul , Sharma, Raghwa , Shvetsov, Yurii B. , Singh, Naveena , Steele, Linda , Stewart, Colin J.R. , Talhouk, Aline , Tan, Adeline , Terry, Kathryn L. , Tołoczko, Aleksandra, Aa, Maaike A. van der , Gorp, Toon Van , Nieuwenhuysen, Els Van , van‐Wagensveld, Lilian, Vergote, Ignace , Wu, Anna H. , Reis, Francisco José Cândido dos , Fasching, Peter A. , Goode, Ellen L. , Goodman, Marc T. , Kommoss, Stefan , Menon, Usha , Sinn, Hans‐Peter , Staebler, Annette , Bowtell, David D.L. , Ramus, Susan J. , Lambrechts, Diether , El‐Bahrawy, Mona , Lee, Cheng-Han , Fereday, Sian , Kennedy, Catherine J , Sasamoto, Naoko , Schildkraut, Joellen M , Talhouk, Aline , Vergote, Ignace , Köbel, Martin , Lambrechts, Diether , Ramus, Susan J , Rodríguez-Antona, Cristina , Menon, Usha , Sinn, Peter , Anglesio, Michael S , Jones, Michael E , Lambrechts, Diether , Brand, Alison H , Bowtell, David D , Nelson, Gregg S , El-Bahrawy, Mona A , Harnett, Paul R , Schoemaker, Minouk J , Goodman, Marc T , Linder, Anna , Cohen, Paul , Kang, Eun‐Young, Ghatage, Prafull , Bolithon, Adelyn , Ataseven, Beyhan , Brooks‐Wilson, Angela , Brucker, Sara Yvonne , Cazorla, Alicia , Conrads, Thomas , Cook, Linda S. , Cramer, Daniel W. , Crowe, Philip John , Cybulski, Cezary , Elishaev, Esther , Erber, Ramona , Fereday, Sián , Gentry‐Maharaj, Aleksandra , Gilks, C. Blake , Group, AOCS, Grube, Marcel , Hein, Alexander , Heitz, Florian , Hernandez, Brenda Y. , Høgdall, Estrid , Høgdall, Claus , Horlings, Hugo , Huzarski, Tomasz , Jewell, Andrea , Kaufmann, Scott H. , Kommoss, Felix , Kruitwagen, Roy F.P.M. , Lubiński, Jan , Modugno, Francesmary , Neuhausen, Susan L. , Olbrecht, Siel , Sonke, Gabe S. , Sundfeldt, Karin , Swerdlow, Anthony J. , Taylor, Sarah E. , Traficante, Nadia , Van de Vijver, Koen , Vierkant, Robert A. , Wang, Chen , Wilkens, Lynne R. , Winham, Stacey J. , Benı́tez, Javier , Berchuck, Andrew , DeFazio, Anna , Gronwald, Jacek , Karlan, Beth Y. , Brenton, James D. , Pharoah, Paul D.P. , Köbel, Martin

Mayo Clinic

Cancer | December 27, 2022 | Volume: 129 | Issue: 5 | Pages: 697-713

10.1002/cncr.34582 | PMID 36572991 Get It

AbstractBackgroundCyclin E1 (CCNE1) is a potential predictive marker and therapeutic target in tubo‐ovarian high‐grade serous carcinoma (HGSC). Smaller studies have revealed unfavorable associations for CCNE1 amplification and CCNE1 overexpression with survival, but to date no large‐scale, histotype‐specific validation has been performed. The hypothesis was that high‐level amplification of CCNE1 and CCNE1 overexpression, as well as a combination of the two, are linked to shorter overall survival in HGSC.MethodsWithin the Ovarian Tumor Tissue Analysis consortium, amplification status and protein level in 3029 HGSC cases and mRNA expression in 2419 samples were investigated.ResultsHigh‐level amplification (>8 copies by chromogenic in situ hybridization) was found in 8.6% of HGSC and overexpression (>60% with at least 5% demonstrating strong intensity by immunohistochemistry) was found in 22.4%. CCNE1 high‐level amplification and overexpression both were linked to shorter overall survival in multivariate survival analysis adjusted for age and stage, with hazard stratification by study (hazard ratio [HR], 1.26; 95% CI, 1.08‐1.47, p = .034, and HR, 1.18; 95% CI, 1.05‐1.32, p = .015, respectively). This was also true for cases with combined high‐level amplification/overexpression (HR, 1.26; 95% CI, 1.09‐1.47, p = .033). CCNE1 mRNA expression was not associated with overall survival (HR, 1.00 per 1‐SD increase; 95% CI, 0.94‐1.06; p = .58). CCNE1 high‐level amplification is mutually exclusive with the presence of germline BRCA1/2 pathogenic variants and shows an inverse association to RB1 loss.ConclusionThis study provides large‐scale validation that CCNE1 high‐level amplification is associated with shorter survival, supporting its utility as a prognostic biomarker in HGSC.
Copy Number Variants Are Ovarian Cancer Risk Alleles at Known and Novel Risk Loci
DeVries, Amber A , Peng, Pei-Chen , Reyes, Alberto Luiz P., Plummer, Jasmine , Davis, Brian , Chen, Stephanie S., Dezem, Felipe Segato , Antonenkova, Natalia, Beckmann, Matthias W. , Beeghly‐Fadiel, Alicia, Bogdanova, Natalia , Bogdanova-Markov, Nadja, Brenton, James D. , Chang‐Claude, Jenny , Dörk, Thilo , Eccles, Diana M, Fasching, Peter A. , Goode, Ellen L. , Goodman, Marc T. , Group, OPAL Study, Grant, Peter , Nagle, C.A., Chevenix-Trench, G, Bowtell, D, Blomfield, Penny, Davis, Alison , Leung, Yee , Livingstone, Karen, O’Neill, Helen C. , Black, Amanda , Hadley, Alison , Shannon, Colleen, Neesham, Deborah, Otton, Geoffrey, Au‐Yeung, George , Goss, Geraldine , Wain, Gerard, Gard, Grace , Robertson, G S M, Lombard, Janine , Tan, Joanne , McNeilage, Jane, Power, J. , Miller, Jessica A., Lamont, John, Wong, Kit Man , Reid, Kate , Milishkin, L, Buck, Martin , Bunting, Michael W, McNally, Orla , Awad, Reda, Mohan, Rahul , Farrell, Rhonda , McIntosh, Rachel, Rome, Robert, Houghton, R., Hogg, Russell , Land, R., Baron‐Hay, Sally , Paramasivum, S, Pather, Selvan , Hyde, Samuel M. , Salfinger, Stuart , Valmadre, Susan, Jobling, Thomas W., Manolitsas, Tom, Bonaventura, T, Group, AOCS, Bowtell, D, Green, A, Webb, P, Gertig, DM, Moore, S., Hung, Jillian A., Harrap, Karen L. , Sadkowsky, T., Malt, M. , Robertson, R. Paul , Bergh, T. Vanden, Jones, Michelle R. , Nattress, K., Chiew, Yoke-Eng, Stenlake, Annie, Ashover, P., Corrish, T., Jackman, Louisa, Ferguson, Kaltin , Martin, Kara, Martyn, Amanda C. , White, Jonathan, Jayde, V., Bowes, Laura, Mamers, Pamela, Galletta, Laura, Giles, Daniel A., Hendley, Joy , Shirley, H., Ball, C., Young, Christian D. , Viduka, S., Bilic, Sanela , Glavinas, Lydia, Brooks, Jacqueline D., Stuart‐Harris, R., Kirsten, Fred, Rutovitz, J , Clingan, P., Proietto, Anthony , Braye, Stephen, Shannon, J., Bonaventura, T, Begbie, Stephen , Hildebrandt, Michelle A.T., Huff, Chad D. , Huntsman, David G., Kar, Siddhartha , Labrie, Marilyne , Lambrechts, Diether , Le, Nhu D. , May, Taymaa, Menon, Usha , Moysich, Kirsten B. , Odunsi, Kunle , Olsson, Håkan , Pearce, Celeste Leigh , Ramus, Susan J. , Ríboli, Elio , Riggan, Marjorie J. , Romieu, Isabelle , Schildkraut, Joellen M. , Sieh, Weiva , Song, Honglin , Sutphen, Rebecca , Terry, Kathryn L. , Thompson, Pamela J., Titus, Linda , Tworoger, Shelley S. , Nieuwenhuysen, Els Van , Edwards, Digna Velez, Wentzensen, Nicolas , Whittemore, Alice S. , Wu, Anna H. , Freedman, Matthew L., Lawrenson, Kate , Easton, Douglas F. , Gayther, Simon A. , Eccles, Diana , Bowtell, David D.L. , Lambrechts, Diether , Dennis, Joe , Plummer, Jasmine T , Anton-Culver, Hoda , Campbell, Ian G , Chenevix-Trench, Georgia , Eliassen, A Heather , Jensen, Allan , Kar, Siddhartha , Menon, Usha , Riboli, Elio , Sieh, Weiva , Webb, Penelope M , Wentzensen, Nicolas , Wolk, Alicja , Ziogas, Argyrios , Lawrenson, Kate , Jones, Michelle R , Dörk, Thilo , Lambrechts, Diether , Ramus, Susan J , Tworoger, Shelley S , Eccles, Diana , Brenton, James D , Moysich, Kirsten , Lambrechts, Diether , Bogdanova, Natalia V , Bowtell, David D , Goodman, Marc T , Tyrer, Jonathan P. , Coetzee, Simon G. , Aben, Katja K.H. , Anton‐Culver, Hoda , Beeghly‐Fadiel, Alicia , Berchuck, Andrew , Bützow, Ralf C. , Campbell, Ian , Chenevix‐Trench, Georgia , Cook, Linda S. , DeFazio, Anna , Doherty, Jennifer A. , Eliassen, A. Heather , Fortner, Renée T. , Giles, Graham G. , Gronwald, Jacek , Group, OPAL Study, Friedländer, Michael , Obermair, Andreas , Nagle, C, Beesley, Vanessa L. , Bowtell, D, Brand, Alison H. , Nicklin, James , Quinn, Michael A. , Williams, M, Hadley, A, Glasgow, A, Garrett, A, Rao, A, Steer, Christopher , Allen, Deborah Emma , Robertson, G, Power, J, Coward, Jermaine , Carter, Jonathan , Lamont, J, Wong, K M, Perrin, Lewis C , Nascimento, M, Buck, M, Harrison, Michelle , Chetty, Naven , Hacker, Neville F. , Harnett, Paul R. , Beale, Philip James , Awad, R, McIntosh, R, Sayer, R, Hogg, R, Hyde, S, Bonaventura, T, Arora, Vivek , Group, AOCS, Bowtell, D, Webb, P, Gertig, Dorota M., Traficante, Nadia , Fereday, Sián , Pandeya, Nirmala , Robertson, R, McKenzie, P, Maidens, J, Sullivan, Helen T. , Alexander, Brian M. , Brown, S, Green, L, Jackman, L, Martyn, A, Ranieri, B, White, J, Giles, D, Alsop, Kathryn , Schmidt, T, Young, C, Tran, H, Rutovitz, J, Glasgow, A, Shannon, J, Bonaventura, T, Stewart, James , Håkansson, Niclas , Hildebrandt, Michelle A.T. , Jensen, Allan , Karlan, Beth Y. , Хуснутдинова, Э. К. , Kiemeney, Lambertus A. , Kjær, Susanne K. , Kupryjańczyk, Jolanta , Lubiński, Jan , Milne, Roger L. , Modugno, Francesmary , Monteiro, Álvaro N.A. , Pejovic, Tanja B. , Sandler, Dale P. , Setiawan, Veronica Wendy , Edwards, Digna R. Velez , Webb, Penelope M. , Wolk, Alicja , Ziogas, Argyrios , Pharoah, Paul D.P.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | October 10, 2022 | Volume: 114 | Issue: 11 | Pages: 1533-1544

10.1093/jnci/djac160 | PMID 36210504 Get It

AbstractBackgroundKnown risk alleles for epithelial ovarian cancer (EOC) account for approximately 40% of the heritability for EOC. Copy number variants (CNVs) have not been investigated as EOC risk alleles in a large population cohort.MethodsSingle nucleotide polymorphism array data from 13 071 EOC cases and 17 306 controls of White European ancestry were used to identify CNVs associated with EOC risk using a rare admixture maximum likelihood test for gene burden and a by-probe ratio test. We performed enrichment analysis of CNVs at known EOC risk loci and functional biofeatures in ovarian cancer–related cell types.ResultsWe identified statistically significant risk associations with CNVs at known EOC risk genes; BRCA1 (PEOC = 1.60E-21; OREOC = 8.24), RAD51C (Phigh-grade serous ovarian cancer [HGSOC] = 5.5E-4; odds ratio [OR]HGSOC = 5.74 del), and BRCA2 (PHGSOC = 7.0E-4; ORHGSOC = 3.31 deletion). Four suggestive associations (P < .001) were identified for rare CNVs. Risk-associated CNVs were enriched (P < .05) at known EOC risk loci identified by genome-wide association study. Noncoding CNVs were enriched in active promoters and insulators in EOC-related cell types.ConclusionsCNVs in BRCA1 have been previously reported in smaller studies, but their observed frequency in this large population-based cohort, along with the CNVs observed at BRCA2 and RAD51C gene loci in EOC cases, suggests that these CNVs are potentially pathogenic and may contribute to the spectrum of disease-causing mutations in these genes. CNVs are likely to occur in a wider set of susceptibility regions, with potential implications for clinical genetic testing and disease prevention.
Identification of Two Genetic Loci Associated with Leukopenia after Chemotherapy in Patients with Breast Cancer
Fasching, Peter A. , Liu, Duan , Scully, Steve, Ingle, James N. , Lyra, Paulo C. , Rack, Brigitte , Hein, Alexander , Ekici, Arif B. , Reis, André , Schneeweiß, Andreas , Tesch, Hans , Heinrich, Georg, Beckmann, Matthias W. , Ruebner, Matthias , Huebner, Hanna , Lambrechts, Diether , Madden, Ebony , Shen, Jess, Romm, Jane, Doheny, Kim, Jenkins, Gregory D. , Cunningham, Julie M. , Janni, Wolfgang , Schaid, Daniel J. , Häberle, Lothar , Weinshilboum, Richard M. , Wang, Liewei , Lambrechts, Diether , Lambrechts, Diether , Li, Liang , Fridley, Brooke L , Cunningham, Julie M , Janni, Wolfgang , Monteiro, Alvaro N , Ingle, J , Lambrechts, Diether , Hein, Alexander , Ekici, Arif B , Reis, André , Morais Lyra, Paulo Cilas , Liu, Duan , Fehm, Tanja , Carlson, Erin E. , Li, Liang , Fridley, Brooke L. , Monteiro, Álvaro N.A. , Weinshilboum, Richard M.

Mayo Clinic

Clinical Cancer Research | June 27, 2022 | Volume: 28 | Issue: 15 | Pages: 3342-3355

10.1158/1078-0432.ccr-20-4774 | PMID 35653140 Get It

Abstract Purpose: To identify molecular predictors of grade 3/4 neutropenic or leukopenic events (NLE) after chemotherapy using a genome-wide association study (GWAS). Experimental Design: A GWAS was performed on patients in the phase III chemotherapy study SUCCESS-A (n = 3,322). Genotyping was done using the Illumina HumanOmniExpress-12v1 array. Findings were functionally validated with cell culture models and the genotypes and gene expression of possible causative genes were correlated with clinical treatment response and prognostic outcomes. Results: One locus on chromosome 16 (rs4784750; NLRC5; P = 1.56E-8) and another locus on chromosome 13 (rs16972207; TNFSF13B; P = 3.42E-8) were identified at a genome-wide significance level. Functional validation revealed that expression of these two genes is altered by genotype-dependent and chemotherapy-dependent activity of two transcription factors. Genotypes also showed an association with disease-free survival in patients with an NLE. Conclusions: Two loci in NLRC5 and TNFSF13B are associated with NLEs. The involvement of the MHC I regulator NLRC5 implies the possible involvement of immuno-oncological pathways.
Identification of a Locus Near ULK1 Associated With Progression-Free Survival in Ovarian Cancer
Quinn, Michael C. , McCue, Karen, Shi, Wei , Johnatty, Sharon E. , Beesley, Jonathan, Civitarese, Andrew, O’Mara, Tracy A. , Glubb, Dylan M. , Armasu, Sebastian M. , Ong, Jue‐Sheng , Lu, Yi , Gao, Bo , Patch, Ann‐Marie , Fasching, Peter A. , Beckmann, Matthias W. , Lambrechts, Diether , Vergote, Ignace , Beeghly‐Fadiel, Alicia, García, María J. , Goodman, Marc T. , Dörk, Thilo , Moysich, Kirsten B. , Pfisterer, Jacobus , Bauman, Klaus, Lester, Jenny , Cunningham, Julie M. , McCauley, Bryan M. , Høgdall, Claus , Schildkraut, Joellen M. , Riggan, Marjorie J. , Terry, Kathryn L. , Webb, Penelope M. , May, Taymaa, Ene, Gabrielle, Huntsman, David G., Woo, Michelle, Carney, Michael E. , Fereday, Sián , Kennedy, Catherine J. , Edwards, Stacey L. , DeFazio, Anna , Goode, Ellen L. , MacGregor, Stuart , Chenevix‐Trench, Georgia , Lambrechts, Diether , Quinn, Michael C J , Ong, Jue-Sheng , Gharahkhani, Puya , Lu, Yi , Fasching, Peter A , Lambrechts, Diether , Vergote, Ignace , Dörk, Thilo , Dürst, Matthias , Modugno, Francesmary , Bois, Andreas du , Karlan, Beth Y , Cunningham, Julie M , Kjaer, Susanne K , Webb, Penelope M , Friedlander, Michael , Glasspool, Rosalind , Hinsley, Samantha , Heitz, Florian , Kennedy, Catherine J , Winham, Stacey J , Fazio, Anna de , Pharoah, Paul D P , MacGregor, Stuart , Lambrechts, Diether , Moysich, Kirsten , O'Mara, Tracy A , Chenevix-Trench, Georgia , Høgdall, Claus K , Fereday, Sian , Goodman, Marc T , Beesley, Jonathan, Tyrer, Jonathan P. , Gharahkhani, Puya , Edwards, Digna R. Velez , Beeghly‐Fadiel, Alicia , Benı́tez, Javier , Modugno, Francesmary , Karlan, Beth Y. , Larson, Melissa C. , Kjær, Susanne K. , Jensen, Allan , Høgdall, Estrid , Berchuck, Andrew , Cramer, Daniel W. , Bjørge, Line , Friedländer, Michael , Pejovic, Tanja B. , Moffitt, Melissa , Glasspool, Rosalind , Heitz, Florian , Winham, Stacey J. , Pharoah, Paul D.P.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | June 23, 2021 | Volume: 30 | Issue: 9 | Pages: 1669-1680

10.1158/1055-9965.epi-20-1817 | PMID 34162658 Get It

Abstract Background: Many loci have been found to be associated with risk of epithelial ovarian cancer (EOC). However, although there is considerable variation in progression-free survival (PFS), no loci have been found to be associated with outcome at genome-wide levels of significance. Methods: We carried out a genome-wide association study (GWAS) of PFS in 2,352 women with EOC who had undergone cytoreductive surgery and standard carboplatin/paclitaxel chemotherapy. Results: We found seven SNPs at 12q24.33 associated with PFS (P < 5 × 10–8), the top SNP being rs10794418 (HR = 1.24; 95% CI, 1.15–1.34; P = 1.47 × 10–8). High expression of a nearby gene, ULK1, is associated with shorter PFS in EOC, and with poor prognosis in other cancers. SNP rs10794418 is also associated with expression of ULK1 in ovarian tumors, with the allele associated with shorter PFS being associated with higher expression, and chromatin interactions were detected between the ULK1 promoter and associated SNPs in serous and endometrioid EOC cell lines. ULK1 knockout ovarian cancer cell lines showed significantly increased sensitivity to carboplatin in vitro. Conclusions: The locus at 12q24.33 represents one of the first genome-wide significant loci for survival for any cancer. ULK1 is a plausible candidate for the target of this association. Impact: This finding provides insight into genetic markers associated with EOC outcome and potential treatment options. See related commentary by Peres and Monteiro, p. 1604
Rare Copy Number Variants (CNVs) and Breast Cancer Risk
Dorling, Leila , Bola, Manjeet, Wang, Qin , Andrulis, Irene L. , Antonenkova, Natalia, Aronson, Kristan J. , Freeman, Laura Beane, Beckmann, Matthias W. , Bojeson, Stig, Chang‐Claude, Jenny , Chenevix‐Trench, Georgia , Collaborators, NBCS, Collée, J. Margriet, Evans, D. Gareth , Fasching, Peter A. , Flyger, Henrik, Hahen, Eric, Haiman, Christopher A. , Hoppe, Reine, Investigators, ACTB, Investigators, kConFab, Jager, Agnes , Johnson, Nichola , Keeman, Renske , Ko, Yon‐Dschun, Kosma, Veli‐Matti , Kristensen, Vessela N. , Kubelka‐Sabit, Katerina , Kurian, Alison, Larson, Nicole L. , Linet, Martha S. , Łukomska, Alicja, Mannermaa, Arto , Mavroudis, Dimitrios, Park‐Simon, Tjoung‐Won , Peterlongo, Paolo , Plaseska-Karanfilska, Dijana, Sawyer, Elinor J. , Schmutzler, Rita K., Shibli, Rana , Soucy, Penny, Tomlinson, Ian , Vachon, Celine M. , Wendt, Camilla, Yang, Xiaohong R. , Easton, Douglas F. , Peterlongo, Paolo , Evans, D Gareth , Chenevix-Trench, Georgia , Sawyer, Elinor J , Dennis, Joe , Tyrer, Jonathan P. , Walker, Logan C. , Michailidou, Kyriaki , Ahearn, Thomas U. , Anton‐Culver, Hoda , Arndt, Volker , Behrens, Sabine , Benı́tez, Javier , Bermisheva, Marina , Bojesen, Stig E. , Brenner, Hermann , Castelao, Jose E. , Clarke, Christine L. , Couch, Fergus J. , Cox, Angela , Cross, Simon S. , Czene, Kamila , Devilee, Peter , Dörk, Thilo , Dossus, Laure , Eliassen, A. Heather , Eriksson, Mikael , Figueroa, Jonine D. , Fletcher, Olivia , Fritschi, Lin , Gabrielson, Marike , Gago-Domínguez, Manuela , García‐Closas, Montserrat , Giles, Graham G. , González‐Neira, Anna , Guénel, Pascal , Hall, Per N , Hollestelle, Antoinette , Hoppe, Reiner , Hopper, John L. , Howell, Anthony , Jakubowska, Anna , John, Esther M. , Jones, Michael E. , Jung, Audrey , Kaaks, Rudolf , Хуснутдинова, Э. К. , Kitahara, Cari M. , Koutros, Stella , Kraft, Peter , Lambrechts, Diether , Manoukian, Siranoush , Margolin, Sara , Milne, Roger L. , Muranen, Taru , Murphy, Rachel A. , Nevanlinna, Heli , Olson, Janet E. , Olsson, Håkan , Perou, Charles M. , Pylkäs, Katri , Rennert, Gad , Saloustros, Emmanouil , Sandler, Dale P. , Schmidt, Marjanka K. , Smeets, Ann , Southey, Melissa C. , Swerdlow, Anthony J. , Tamimi, Rulla M. , Taylor, Jack A. , Teras, Lauren R. , Terry, Mary Beth , Troester, Melissa A. , Truong, Thérèse , Vachon, Celine M. , Wendt, Camilla, Winqvist, Robert , Wolk, Alicja , Zheng, Wei , Ziogas, Argyrios , Simard, Jacques , Dunning, Alison M. , Pharoah, Paul D.P.

Mayo Clinic

No container title available | June 22, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-602209/v1 Get It

Abstract BackgroundCopy number variants (CNVs) are pervasive in the human genome but potential disease associations with rare CNVs have not been comprehensively assessed in large datasets. We analysed rare CNVs in genes and non-coding regions for 86,788 breast cancer cases and 76,122 controls of European ancestry with genome-wide array data.ResultsGene burden tests detected the strongest association for deletions in BRCA1 (P= 3.7E-18). Nine other genes were associated with a p-value < 0.01 including known susceptibility genes CHEK2 (P= 0.0008), ATM (P= 0.002) and BRCA2 (P= 0.008). Outside the known genes we detected associations with p-values < 0.001 for either overall or subtype-specific breast cancer at nine deletion regions and four duplication regions. Three of the deletion regions were in established common susceptibility loci.ConclusionsThis is the first genome-wide analysis of rare CNVs in a large breast cancer case-control dataset. We detected associations with exonic deletions in established breast cancer susceptibility genes. We also detected suggestive associations with non-coding CNVs in known and novel loci with large effects sizes. Larger sample sizes will be required to reach robust levels of statistical significance.
Mutations in BRCA1/2 and Other Panel Genes in Patients With Metastatic Breast Cancer —Association With Patient and Disease Characteristics and Effect on Prognosis
Fasching, Peter A. , Yadav, Siddhartha , Wunderle, Marius , Häberle, Lothar , Hart, Steven N. , Rübner, Matthias, Polley, Eric C. , Lee, Kun Y. , Hadji, Peyman , Hübner, H., Tesch, Hans , Ettl, Johannes , Overkamp, Friedrich , Ekici, Arif B. , Volz, Bernhard , Uhrig, Sabrina , Lüftner, Diana , Müller, Volkmar , Belleville, Erik, Kolberg, Hans‐Christian , Beckmann, Matthias W. , Hartmann, Arndt , Janni, Wolfgang , Taran, Florin‐Andrei , Fehm, Tanja , Wallwiener, D. , Schneeweiß, Andreas , Chen, Chen , Hu, Chunling , Wunderle, Marius , Hart, Steven N , Polley, Eric C , Lee, Kun Y , Gnanaolivu, Rohan D., Hübner, Hanna , Lux, Michael P , Ekici, Arif B , Müller, Volkmar , Untch, Michael , Kolberg, Hans-Christian , Reis, André , Schneeweiss, Andreas , Hartkopf, Andreas D , Couch, Fergus J. , Chen, C , Yadav, Siddhartha , Fehm, Tanja , Hu, Chunling , Gnanaolivu, Rohan , Lux, Michael P. , Wallwiener, Markus , Untch, Michael , Reis, André , Wimberger, Pauline , Brucker, Sara Yvonne , Couch, Fergus J.

Mayo Clinic

Journal of Clinical Oncology | March 29, 2021 | Volume: 39 | Issue: 15 | Pages: 1619-1630

10.1200/jco.20.01200 | PMID 33780288 Get It

PURPOSE Among patients with metastatic breast cancer (mBC), the frequency of germline mutations in cancer susceptibility genes and the clinical relevance of these mutations are unclear. In this study, a prospective cohort of patients with mBC was used to determine mutation rates for breast cancer (BC) predisposition genes, to evaluate the clinical characteristics of patients with mutations, and to assess the influence of mutations on patient outcome. PATIENTS AND METHODS Germline DNA from 2,595 patients with mBC enrolled in the prospective PRAEGNANT registry was evaluated for mutations in cancer predisposition genes. The frequencies of mutations in known BC predisposition genes were compared with results from a prospective registry of patients with nonmetastatic BC sequenced using the same QIAseq method and with public reference controls. Associations between mutation status and tumor characteristics, progression-free survival, and overall survival were assessed. RESULTS Germline mutations in 12 established BC predisposition genes (including BRCA1 and BRCA2) were detected in 271 (10.4%) patients. A mutation in BRCA1 or BRCA2 was seen in 129 patients (5.0%). BRCA1 mutation carriers had a higher proportion of brain metastasis (27.1%) compared with nonmutation carriers (12.8%). Mutations were significantly enriched in PRAEGNANT patients with mBC compared with patients with nonmetastatic BC (10.4% v 6.6%, P < .01). Mutations did not significantly modify progression-free survival or overall survival for patients with mBC. CONCLUSION Multigene panel testing may be considered in all patients with mBC because of the high frequency of germline mutations in BRCA1/2 and other BC predisposition genes. Although the prognosis of mutation carriers and nonmutation carriers with mBC was similar, differences observed in tumor characteristics have implications for treatment and for future studies of targeted therapies.